Back

Galectin-3 in the human atria and serum of patients with atrial fibrillation does not reflect progression of the fibrotic substrate

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 5 - Mechanism of arrhythmia in atrial fibrillation . New data on remodelling biomarkers and anti-arrhythmic drugs Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Wouter Berger

St Antonius Hospital, Nieuwegein (Netherlands (The))

28 More presentations in this session

Presentation thumbnail
Increased arrhythmia stability is associated with risk-factor specific structural remodelling in a porcine model of arterial hypertension and atrial fibrillation
Doctor M. Manninger (Graz, AT)
Abstract Slides
Presentation thumbnail
Inhibition of small conductance Ca2+-activated K+-Channels converts and prevents reinduction of atrial fibrillation in pigs where vernakalant fails
Doctor J. Diness (Frederiksberg, DK)
Abstract
Presentation thumbnail
Inducibility of atrial fibrillation after epicardial injection of the new pharmaceutical composition containing botulinum toxin into epicardial fat pads
Doctor A. Romanov (Novosibirsk, RU)
Abstract
Presentation thumbnail
Glucagon-like-peptide-1 (GLP-1) Suppresses the Induction of Atrial Fibrillation in Canine Model of Atrial Fibrillation.
Doctor H. Nakamura (Sagamihara, JP)
Abstract Slides
Presentation thumbnail
Can we predict the effect of antiarrhythmic pharmacotherapy in atrial fibrillation and metabolic syndrome patients: focus on galectin-3
Assistant Professor V. Ionin (Saint Petersburg, RU)

Access the full session

Session thumbnail
Poster session 5 - Mechanism of arrhythmia in atrial fibrillation . New data on remodelling biomarkers and anti-arrhythmic drugs

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources